Clearside Biomedical (NASDAQ:CLSD) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”
Following the administrative process, the new U.S. patent would provide intellectual property protection for methods of treating the posterior ocular disorder, uveitis, by non-surgically administering the corticosteroid, triamcinolone acetonide, to the suprachoroidal space of the eye.
“This, the ninth patent allowance in the U.S. related to our proprietary approach for the treatment of blinding diseases, represents another important addition to our intellectual property estate,” president and CEO, Daniel White, said in a statement.
The new patent would represent one in a series of filings protecting the use of the suprachoroidal space as a location in the eye to dose drug that provides for higher bioavailability to target retinal and choroidal diseases and retains drug away from the anterior segment where side effects may occur, regardless of the method of administration.
Suprachoroidally administered CLS-TA, Clearside’s proprietary suspension formulation of triamcinolone acetonide, used either alone or together with an intravitreal anti-VEGF agent, is part of the company’s pipeline for the treatments of unmet or underserved blinding eye diseases where the pathologies manifest in the choroid or retina.
“As we continue to advance our late-stage development programs for CLS-TA, a core component of our growth strategy is to ensure that the corresponding potential market opportunities are well protected,” Mr. White added.